Inhibition of Catabolic Pathway of 5‐Fluorouracil by 3‐Cyano‐2,6‐dihydroxypyridine in Human Lung Cancer Tissues
暂无分享,去创建一个
[1] K. Tatsumi,et al. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. , 1993, Journal of biochemistry.
[2] G. Bodey,et al. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. , 1986, Anticancer research.
[3] F N Naguib,et al. Enzymes of uracil catabolism in normal and neoplastic human tissues. , 1985, Cancer research.
[4] C. Heidelberger,et al. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. , 1982, Cancer research.
[5] Y. Maehara,et al. Metabolism of 5-fluorouracil in various human normal and tumor tissues. , 1981, Gan.
[6] J. Laskin,et al. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. , 1980, Cancer research.
[7] G. L. Carter,et al. Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells. , 1979, Cancer research.
[8] K. Randerath,et al. Effects of 5-fluorouridine on modified nucleosides in mouse liver transfer RNA. , 1976, Biochemical and biophysical research communications.
[9] C. Heidelberger,et al. Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. , 1961, The Journal of biological chemistry.
[10] C. Heidelberger,et al. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. , 1960, The Journal of biological chemistry.